Tyvaso
Payments companies reported to CMS as associated with Tyvaso. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tyvaso, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tyvaso
These are the largest totals companies reported as associated with Tyvaso. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Steven Nathan | Falls Church, VA | Pulmonary Disease | $115,438.61 |
| Abhijit Raval | Anderson, SC | Pulmonary Disease | $96,644.59 |
| Lana Melendres Groves | Albuquerque, NM | Pulmonary Disease | $87,975.75 |
| Jason Stienecker | Lima, OH | Pulmonary Disease | $82,956.72 |
| Rajan Saggar | Los Angeles, CA | Pulmonary Disease | $79,727.02 |
| Rodolfo Estrada Anzueto | San Antonio, TX | Pulmonary Disease | $68,637.65 |
| John Ryan | Salt Lake City, UT | Cardiovascular Disease | $62,427.02 |
| Ricardo Restrepo-Jaramillo | Tampa, FL | Pulmonary Disease | $58,554.46 |
| Hunter Champion | Columbus, GA | Cardiovascular Disease | $58,053.62 |
| Mary Scholand | Salt Lake City, UT | Pulmonary Disease | $55,368.94 |
Prescribed Tyvaso?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.